1,084 reports of this reaction
2.2% of all CANAGLIFLOZIN reports
#8 most reported adverse reaction
GANGRENE is the #8 most commonly reported adverse reaction for CANAGLIFLOZIN, manufactured by Janssen Pharmaceuticals, Inc.. There are 1,084 FDA adverse event reports linking CANAGLIFLOZIN to GANGRENE. This represents approximately 2.2% of all 49,711 adverse event reports for this drug.
Patients taking CANAGLIFLOZIN who experience gangrene should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GANGRENE is a less commonly reported adverse event for CANAGLIFLOZIN, but still significant enough to appear in the safety profile.
In addition to gangrene, the following adverse reactions have been reported for CANAGLIFLOZIN:
GANGRENE has been reported as an adverse event in 1,084 FDA reports for CANAGLIFLOZIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
GANGRENE accounts for approximately 2.2% of all adverse event reports for CANAGLIFLOZIN, making it a notable side effect.
If you experience gangrene while taking CANAGLIFLOZIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.